Comparison of prostate cancer patient’s survival in Belarus and Lithuania

• Authors: Giedre Smailyte , Yury Averkin , Ilya Veyalkin , Sergey Krasny , Karolis Ulinskas
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Prostate cancer; Relative survival

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2011
• Volume: 6
• Issue: 5
• Pages: 545-549

Dates

published

1 - 10 - 2011

online

9 - 8 - 2011

Contributors

author

Giedre Smailyte

• Lithuanian Cancer Registry, Institute of Oncology, Vilnius University, LT-08660, Vilnius, Lithuania

author

Yury Averkin

• N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus

author

Ilya Veyalkin

• N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus

author

Sergey Krasny

• N.N. Alexandrov National Cancer Center of Belarus, 223040, Minsk, Belarus

author

Karolis Ulinskas

• Lithuanian Cancer Registry, Institute of Oncology, Vilnius University, LT-08660, Vilnius, Lithuania

References

• [1] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food. Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511[WoS][Crossref]
• [2] Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581–592. http://dx.doi.org/10.1093/annonc/mdl498[Crossref]
• [3] Coebergh J.W.W., Sant M., Berrino F., Verdecchia A., Survival of adult cancer patients in Europe diagnosed from 1978–1989: the EUROCARE II study, Eur. J. Cancer, 1998, 34, 2137–2178. http://dx.doi.org/10.1016/S0959-8049(98)99063-3[Crossref]
• [4] Berrino F., Capocaccia R., Coleman M.P., Estève J., Gatta G., Hakulinen T., et al., Survival of cancer patients in Europe. The EUROCARE-3 study, Annal. Oncol., 2003, 14(suppl 5), v9–155. http://dx.doi.org/10.1093/annonc/mdg750[Crossref]
• [5] Coleman M.P., Gatta G., Verdecchia A., Estève J., Sant M., Storm H., et al., EUROCARE-3 summary: cancer survival at the end of 20th century, Annal. Oncol., 2003, 14(suppl 5), v128–149. http://dx.doi.org/10.1093/annonc/mdg756[Crossref]
• [6] Ederer F., Axtell L.M., Cutler S.J., The relative survival rate: a statistical methodology, Natl. Cancer Inst. Monogr., 1961, 6, 101–121 [PubMed]
• [7] Dickman P., [Accessed 29 June 2009], Available at http://www.pauldickman.com.
• [8] Sant M, Capocaccia R, Coleman MP, Berrino F., Gatta G., Micheli A., et al., Cancer survival increases in Europe, but international differences remain wide, Eur. J. Cancer, 2001, 37, 1659–1667. http://dx.doi.org/10.1016/S0959-8049(01)00206-4[Crossref]
• [9] Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al., Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data, Lancet Oncol., 2007, 8, 784–796. http://dx.doi.org/10.1016/S1470-2045(07)70246-2
• [10] Gondos A., Bray F., Brewster D.H., Coebergh J.W., Hakulinen T., Janssen-Heijnen M.L., et al., Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries, Eur. J. Cancer, 2008, 44, 1463–1475. http://dx.doi.org/10.1016/j.ejca.2008.03.010[Crossref]
• [11] Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival, Cancer, 2004, 101, 3–27. http://dx.doi.org/10.1002/cncr.20288[Crossref]
• [12] Verdecchia A., Guzzinati S., Francisci S., De Angelis R., Bray F., Allemani C., et al., Survival trends in European cancer patients diagnosed from 1988 to 1999, Eur. J. Cancer, 2009, 45, 1042–1066. http://dx.doi.org/10.1016/j.ejca.2008.11.029[Crossref]
• [13] Brenner H., Arndt V., Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis, J. Clin. Oncol., 2005, 23, 441–447. http://dx.doi.org/10.1200/JCO.2005.11.148[Crossref]
• [14] Gondos A., Bray F., Hakulinen T., Brenner H., Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis, Ann. Oncol., 2009, 20, 564–573. http://dx.doi.org/10.1093/annonc/mdn639[Crossref][WoS]
• [15] D’Ambrosio G., Samani F., Cancian M., De Mola C., Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database, Eur. J. Cancer Prev., 2004, 13, 383–386. http://dx.doi.org/10.1097/00008469-200410000-00005[Crossref]
• [16] Etzioni R., Penson D.F., Legler J.M., Overdiagnosis due to prostate specific antigen screening: lessons from U.S. prostate cancer incidence trends, J. Natl. Cancer Inst., 2002, 94, 981–990. [Crossref]
• [17] Gavin A., McCarron P., Middleton R.J., Savage G., Catney D., O’Reilly D., et al., Evidence of prostate cancer screening in a UK region, BJU Int., 2004, 93, 730–734. http://dx.doi.org/10.1111/j.1464-410X.2003.04716.x[Crossref]
• [18] Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., Mason M.D., Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst. Rev., [2006CD006019].
• [19] Mike S., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D., Chemotherapy for hormone-refractory prostate cancer, Cochrane Database Syst. Rev., [2006CD005247].
• [20] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-011-0058-5